Journal Article

Short-term progression of interstitial lung disease in systemic sclerosis predicts long-term survival in two independent clinical trial cohorts

Schraufnagel, Dean E, Elashoff, Robert M, Li, Ning, Goldmuntz, Ellen, Clements, Philip J, Khanna, Dinesh, Sullivan, Keith M, Tashkin, Donald P, Arami, Shiva, Pinckney, Ashley, Sim, Myung, Steen, Virginia, Furst, Daniel E, Roth, Michael D, Keyes-Elstein, Lynette, Hsu, Vivien, Volkmann, Elizabeth R

2019

Overview

ObjectiveTo assess survival and identify predictors of survival in patients with systemic sclerosis-interstitial lung disease (SSc-ILD) who participated in the Scleroderma Lung Studies (SLS) I and II.MethodsSLS I randomised 158 patients with SSc-ILD to 1  year of oral cyclophosphamide (CYC) vs placebo. SLS II randomised 142 patients to 1 year of oral CYC followed by 1 year of placebo vs 2 years of mycophenolate mofetil. Counting process Cox proportional hazard modelling identified variables associated with long-term mortality in SLS I and II. Internal validation was performed using joint modelling.ResultsAfter a median follow-up of 8 years, 42% of SLS I patients died, and when known the cause of death was most often attributable to SSc. There was no significant difference in the time to death between treatment arms in SLS I or II. Higher baseline skin score, older age, and a decline in the forced vital capacity (FVC) and the diffusing capacity for carbon monoxide (DLCO) over 2 years were independently associated with an increased risk of mortality in SLS I. The Cox model identified the same mortality predictor variables using the SLS II data.ConclusionIn addition to identifying traditional mortality risk factors in SSc (skin score, age), this study demonstrated that a decline in FVC and DLCO over 2 years was a better predictor of mortality than baseline FVC and DLCO. These findings suggest that short-term changes in surrogate measures of SSc-ILD progression may have important effects on long-term outcomes.

• Publisher: Elsevier Limited
• Subject: Adult / Arthritis / Carbon monoxide / Carbon Monoxide - analysis / Clinical trials / Cyclophosphamide / Cyclophosphamide - administration & dosage / Disease Progression / Drug Administration Schedule / Dyspnea / Female / Health risk assessment / Humans / Immunosuppressive Agents - administration & dosage / Lung diseases / Lung Diseases, Interstitial - drug therapy / Lung Diseases, Interstitial - etiology / Lung Diseases, Interstitial - mortality / Male / Middle Aged / Mortality / Mycophenolate mofetil / Mycophenolic acid / Mycophenolic Acid - administration & dosage / Patients / Proportional Hazards Models / Pulmonary Diffusing Capacity / Risk Factors / RNA polymerase / Scleroderma / Scleroderma, Systemic - complications / Scleroderma, Systemic - drug therapy / Scleroderma, Systemic - mortality / Short term / Skin / Skin - pathology / Stem cells / Survival / Systematic review / Systemic sclerosis / Time Factors / Transplants & implants / Treatment Outcome / Vital Capacity